Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Hikma Pharmaceuticals Plc Enters Ethiopian Pharmaceutical Market Through Joint Venture With MIDROC Group


Wednesday, 18 Sep 2013 02:00am EDT 

Hikma Pharmaceuticals Plc announced that it has signed a 50:50 joint venture (JV) agreement with MIDROC Pharmaceuticals Limited, a member of Sheikh Mohammed Hussein Al Amoudi's MIDROC Group (MIDROC), to establish a presence in the Ethiopian pharmaceutical market. The JV will be called HikmaCure. Over the next five years, HikmaCure will establish an Ethiopian operating company, build a local manufacturing facility and will begin marketing and distributing pharmaceutical products in Ethiopia. In the short term, MIDROC will work with Hikma and HikmaCure to register, market and distribute Hikma's products in the Ethiopian market. Hikma and MIDROC will invest in HikmaCure in equal proportions and have committed to provide up to $22.3 million each in cash. The funds will be invested over time and will be used to build and fit-out a local manufacturing and distribution facility in Ethiopia and to provide working capital support for the operations of HikmaCure. The facility is expected to begin commercial production in 2017.